who should not take glp 1 medications Chart: in 8 Americans Now Use GLP-1 Drugs for Weight Loss Wait - Maybe You Should

The market has witnessed explosive growth, particularly with the emergence of dual- and tri-agonist formulations and extended applications in obesity, metabolic syndrome, and even addiction and Alzheimers disease

Molecular Nutrition & Food Research , 61 (3), 1600471

Recent litigation updates have reported that the federal vision-loss MDL involves drugs including Ozempic, Wegovy, Saxenda, and Trulicity, though semaglutide remains central to the NAION discussion

But differences like injection frequency, FDA indications, side effects, and insurance coverage can vary wildly, which is why your doctor needs to tailor the prescription to your unique profile

There were no significant differences in the incidence of total or hip fracture between the calorie restriction and control groups

Nutrition and behavior change remain foundational, whether someone chooses to use a GLP-1 or not. In the first nine months of 2025, major pharmaceutical companies spent more than $700 million advertising GLP-1 medications2, with Eli Lilly spending approximately $34 million on television spots in January 2026.3 Yet the 2026 Virta Vitals report suggests that growing awareness of GLP-1s has not necessarily translated into greater willingness to use them